SEC Form 4 · accession 0001185185-16-005908
Entia Biosciences, Inc. · ERGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marvin S Hausman M.D.
Officer — Chairman,Chief Sci/Tech Offc
Period of report
Dec 5, 2016
Accepted (ET)
Dec 6, 2016 · 9:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001408299
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10% ConvertibleF1 | — | Dec 5, 2016 | P | — | A | Dec 5, 2016 | Dec 5, 2017 | Common Stock | — | — | D |
| WarrantF2 | $0.10 | Dec 5, 2016 | P | 40,000 | A | Dec 5, 2016 | Dec 5, 2021 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Holder has option of repayment or conversation into securities of the subject company's next financing. Terms and underlying securities of next financing, if and when such financing occurs, have yet to be determined.
- F2As part of Unit.